Asceneuron has the mission to develop effective therapeutics for Alzheimer’s disease and related neurodegenerative diseases such as tauopathies. We deliberately focus on areas of high unmet medical need and aspire to become a leading biotech company specialized in small molecule drug discovery for neurodegeneration therapeutics.

Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies worldwide. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.